OCUP News and Press, Ocuphire Pharma Inc Com From 01/26/23

Ocuphire Pharma ( NASDAQ: OCUP ) reached a one-month low Thursday even as Cantor Fitzgerald reaffirmed its Overweight rating and a 12-month price target of $24 despite a setback for the company’s eye disease therapy APX3330 in a Phase 2 trial. Announcing topline data Wednes...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Inhibikase Therapeutics (NASDAQ: IKT ) stock is falling on Thursday after the company announced a registered direct offering and private placement . Starting with the registered direct offeri...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Ocuphire Pharma (NASDAQ: OCUP ) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial . The clinical trial evaluated the use of APX3330 as a treatment fo...

Ocuphire Pharma ( NASDAQ: OCUP ) is down 31% in after-hours trading after reporting that a phase 2 trial for an oral diabetic retinopathy candidate missed the primary endpoint. The primary endpoint for APX3330 was a a precedented endpoint for local administration of anti-VEGF intr...

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment Oral APX3330 Demonstrated Favorable Safety and Tolerability Allowing for a Potential Attracti...

Nyxol ® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision Launch of Presbyopia Phase 3 Program Supported by Positive Clinical Results that Demonstrated Durable Efficacy and Favorable Safety Profile FARMING...

FARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced the submission of a...

FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Soo...

Ocuphire Pharma, Inc. ( NASDAQ: OCUP ), a company focused on eye disorders, jumped ~24% pre-market Tuesday after announcing that Viatris ( NASDAQ: VTRS ) has joined hands to commercialize its lead asset Nyxol once approved. The transaction is part of an exclusive...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday! Moving stocks this morning are earnings reports, stock of...